Attovia Therapeutics, Inc. Listed Primary

What the company does

Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. Using its ATTOBODY biparatopic biologics platform, which it in-licensed from Alamar Biosciences, Inc., the company has nominated three product candidates within its first two years, including ATTO-1310, an IL-31-targeting Fc-fusion protein currently in a Phase 1 clinical trial for chronic pruritus and high-itch atopic dermatitis. Additional candidates ATTO-2306 (an IL-13/IL-31 bispecific) and ATTO-1091 (a TL1A/IL-23/integrin α4β7 trispecific) are in IND-enabling studies for atopic dermatitis and inflammatory bowel disease, respectively.

Use of proceeds

The company intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to advance the clinical development of ATTO-1310, ATTO-2306, and its research pipeline, including ATTO-1091, for other research and development activities, as well as for working capital and for other general corporate purposes.

Underwriters

Extracted from 424B4 0001193125-26-334997, filed Aug 5, 2026 and verified against that filing text.

Key risk factors

• Limited use of net operating losses

  “even if we attain profitability, we may be unable to use all or a material portion of our net operating losses and other tax attributes, which could adversely affect our future cash flows.”

• Fluctuating operating results

  “Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.”

• Inaccurate market opportunity estimates

  “Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.”

• No active public trading market

  “No public market for our common stock currently exists, and an active and liquid trading market for our common stock may never develop.”

• Immediate and substantial dilution

  “You will experience immediate and substantial dilution as a result of this offering and raising additional capital in the future may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.”